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FIRST INTERNATIONAL SYMPOSIUM ON PEDIATRIC IBDnot universal. Current study aimed to characterize not only the inci-
dence, but also the clinical picture of IBD through 1987-2003 in a large
pediatric population in Finland.
Methods: Data was collected from the patient discharge and medical
records at the two largest University Hospitals in Finland. The study
population covered a total of 619, 340 children, representing 56% of the
children aged < 18 years in the whole country. All cases diagnosed with
IBD in 1987-2003 were reviewed. Clinical, endoscopic and histological
data were collected. Incidence rates were estimated based on statistical
assumptions.
Results: A total of 604 cases with IBD were diagnosed during the
17-year period. All these patients had undergone endoscopy. The
diagnosis was CD in 203 (34%) cases, UC in 317 (52%) cases, and
indeterminate colitis (IC) in 83 (14%) cases. The mean annual incidence
rate increased from 3.9/100 000 (95% CI 2.5-5.8) in 1987 to 7.0/100 000
(CI 5.0-9.4) in 2003 (P < 0.001). The majority of cases were aged from
12 to < 15 years (N ¼ 200, 33%). Of cases 5.1% were less than 3 years
and 14% less than 6 years of age. IC was most common in the very
young children; 29% of all IBD cases less than 3 years of age had IC. Of
the patients 97% had been followed up until the age of 18 years in the
hospitals after the initial diagnosis (median follow up 3.1 years). Of all
cases 45.2% were initially treated with steroids whereas 17.8% received
immunosuppressive agents at the end of the follow-up. Operations had
been performed in 21% of the cases before the age of 18. The median
time interval from the diagnosis to the first operation was 1.8 years
(range 7.8 years).
Conclusions: The incidence of pediatric IBD almost doubled in
Finland from 1987 to 2003. Surgical intervention was common early in
the disease course.
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Aim: Evaluation of the treatment effectiveness and side effects of
episodic infliximab treatment in paediatric IBD patients.
Methods: Retrospective study collecting data on clinical evolution,
nutritional status and growth of 12 IBD patients <18y treated with
infliximab infusions (2002-2006) (on a total of 37).
Results: 11 Crohn’s disease (10M) and 1 ulcerative colitis (1F) were
started on infliximab because of partial or total steroid dependence. All
had maintenance treatment with mesalazine and azathioprine. Modulen
was used as adjuvant therapy. Median age at diagnosis: 11.9 y (10.5-
14.1). Median age at start of infliximab treatment: 14.3y (12.8-17.8).
Repeated infliximab infusions were administered on clinical demand.
Median follow-up since infliximab: 21m (3m-4y). Complete remission
(CR¼ total regression of symptoms 30d after infliximab infusion) was
observed in 58% (7/12), partial remission (PR¼ regression of symp-
toms) in 33% (4/12) and no response in 1/12. Steroid withdrawal was
possible in all infliximab treated patients. Side effects in 3/12: 2
immediate allergic reactions (future infusions were continued with
concomitant use of oral antihistaminics and IV steroids), 1 patient with
serum sickness & arthritis (stopped). 9/11 remaining patients continue
to receive infliximab every 2-3m with concomitant azathioprine treat-
ment. Growth improved significantly within 3m after start in the CR
group but not in the PR group.
Conclusions: These results confirm a good short term response to
infliximab in paediatric patients with steroid dependent IBD. Side
effects were comparable to what is known in adult patients. Many
patients remain infliximab dependent. Hence, long term effects, now
unknown, are relevant, necessitating careful follow-up of these patients.
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Inflammatory bowel diseases (IBD) represent an aberrant immune
response by the mucosal immune system to luminal bacteria. Pre-
viously, we have compared the immunological activity of buccal
epithelial cells (BEC) from children with IBD and adults with Crohn’s
disease. Only buccal epithelial cells from children with Crohn’s disease
exhibited enhanced production of the chemokines CXCL-8, CXCL-9,
and CXCL-10 whereas BEC from pediatric ulcerative colitis patients,
and adult Crohn’s disease patients did not. In vitro stimulation with
bacterial stimuli such as lipopolysaccharide or zymosan further
increased chemokine release by cells from pediatric Crohn’s disease
patients only.
Next, we determined whether the enhanced chemokine production is
specifically associated with pediatric onset of Crohn’s disease and
present throughout life, or that this enhanced activity is exclusively
present during disease in childhood.
Buccal epithelial cells were obtained from 12 adults with Crohn’s
disease. Of them, 4 had developed CD before the age of 16 years and 8
were older than 20 years of age at CD onset. Cells were cultured with
and without microbial stimulation. CXCL-8 levels were determined at
24h in culture supernatants by ELISA.
Our preliminary data suggest that the enhanced immunological
response of the BEC in pediatric CD is no longer present in adult life.
None of the pediatric onset patients showed enhanced levels of CXCL-
8, either spontaneously or in response to microbial stimulation. These
results may reveal immunological alterations within the epithelial cells
that are specifically associated with pediatric IBD.
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Flora composition may contribute to the pathogenesis of Crohn’s
disease (CD). Interventions with pre-, pro- and synbiotics attempt to
beneficially modify microbial metabolic activity. Stable isotopes mark
the metabolism of intestinal bacteria: 13C-lactose ureide (LU) indicates
orocaecal transit time (OCTT) based on exhaled 13CO2,
15N LU colonic
NH3 metabolism based on 15N urinary levels. 13C LU and 15N LU are
metabolized by the flora of healthy children (1). Pre and probiotics
increase bacterial N incorporation, resulting in reduced urinary 15N-
excretion in healthy adults (2).
Our aim was to assess the effect of pre, pro and synbiotics on the flora
of pediatric CD patients using these biomarkers. Standard test meal
(pancake with 250 mg 13C LU and 75 mg 15N LU) and collection
methods (breath samples for 13CO2 0-10 hrs and urinary collection for
15N 0-48 hrs) were used (1,2). We studied 12 healthy children (6 boys-
mean age 9 yrs, range 6-12 yrs) and 12 patients with inactive CD
(10 boys, mean age 13,4 yrs, range 5-18 yrs, mean PCDAI: 7,5).
Informed consent/assent were obtained. All children were studied in
basal conditions. CD patients performed additional tests after placebo:
maltodextrine 8g/d, prebiotic: oligofructose-enriched inulin (Synergy 1)
8 g/d, probiotics: Lactobacillus rhamnosus 80% and Lactobacillus
acidophilus 20% at 6.109 CFU/d (Bacilac) and synbiotics: a combi-
nation of both. Test products were administered in random order for
2 wks, with 2 wks wash out intervals. In healthy children 13C LU yielded
13CO2 in expired air in all but one (mean OCTT: 278,2 65,9 min)
and 15N LU resulted in 51,65  11,45% dose 15N urinary recovery
(0-48 hrs). In all but one, CD patients who completed the study 13C LU
breath test yielded very delayed (>360 min) or no 13CO2 exhalation for
basal condition, placebo, pre, pro and synbiotics in 9, 5, 8, 9, 7 subjects
respectively. In contrast, 15N LU excretion in basal conditions (#10) was
similar to healthy children (47,6116,81; p¼NS). Intervention with
placebo, pre and probiotics did not change 15N % dose urinary excretion
(0-48 hrs placebo: 48,7028,99; prebiotic: 56,16 14,25; probiotics:thorized reproduction of this article is prohibited.
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